Blog
Brand New Biglaw Firm Delights With Associate Bonuses
It was only earlier this year that the Biglaw world got its latest mega firm following the merger of Herbert Smith Freehills and Kramer...
The Current Legal Landscape of the 340B Drug Pricing Program
The federal 340B Drug Pricing Program ("340B Program") was created by Congress in 1992 through an amendment to the Public Health Servic...
California SB 243: Setting New Standards for Regulating and Ensuring Integrity of AI Companion Chatbots
The rapid advancement of artificial intelligence (“AI”) has spurred remarkable innovation for the healthcare industry, while also resul...
Produkthaftung im Hochsicherheitssektor: KI-bedingte Risiken nach deutschem und europäischem Recht sicher steuern
Neue Technologien treffen auf neue Haftungsfragen: Der rasante technologische Wandel und die zunehmende Komplexität der Regulierung ver...
Navigating product liability in high-security sectors: Addressing AI-driven risks under German and European law
New technologies meet new liability frontiers: Rapid technological change and increasing regulatory complexity are reshaping the risk l...
Asia Energy Trends for 2026
Asia power demand is expected to grow again in 2026, as digital and industrial activity accelerates. The region also faces an increase ...
In 2025, Trump’s Justice Department Was Fodder For An Endless Parade Of Legal Blunders And Public Embarrassment
Ed. note: Welcome to our daily feature, Quote of the Day.
They shoot first, they aim later, and even then, they miss. Because there is ...
Ethical Leadership in the AI Era: Inside the 2025 NAVEX + Granite GRC Executive Forum
At the historic Union League of Philadelphia, senior compliance and risk leaders gathered for the NAVEX + Granite GRC Executive Forum, ...
Medical Devices updates: Phase II consultation on Medical Devices Regulations amendments, medical device licences guidance and IMDRF table of contents guidance
On November 17, 2025, Health Canada proposed Phase II amendments to the Medical Devices Regulations (MDR). The first phase of amendment...
Most Favored Nation Drug Pricing and Manufacturer Agreements
Most Favored Nation or "MFN" drug pricing is a policy through which prescription drug prices in the United States are aligned with the ...